A promising vaccine that clears an HIV-like virus from monkeys is closer to clinical trial human testing.
List view / Grid view
Filter the results
The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice.
A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled.
Using exclusively male animals in experiments biases results, argues Rebecca Shansky.
Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use.
A new report reveals a thriving service and supply sector for the UK in addition to its research and development biotechs.
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
A new method of assessing the actions of medicines by matching them to their unique protein receptors could accelerate drug development.
In a recent study more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies.
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...